Founded in 2005, AnaptysBio is a privately-held therapeutic antibody company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body’s natural process for generating potent antibodies to fight disease. The Company’s SHM-XEL™ platform couples SHM with other leading-edge technologies to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used for both discovery of new antibodies and optimization of existing antibodies to generate candidates with desired binding and specificity properties for therapeutic applications.
Our team has extensive technical and business experience in the generation and development of therapeutic antibodies. We have established broad intellectual property around SHM and our SHM-XEL™ platform, and are building a pipeline of novel therapeutic antibodies.